The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Open accessAbstract
Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
Self-citationPeiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Self-citationRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13615-x · Cited by 1,158
Donnelly, C. A., Ghani, A. C., Leung, G. M., Hedley, A. J., Fraser, C., Riley, S., Abu-Raddad, L. J., Ho, L.-M., Thach, T.-Q., Chau, P., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13410-1 · Cited by 940 · cited 2×
“Since all age groups are affected and a high fatality is noted in the elderly and those with co-morbidities (Donnelly et al., 2003) , there is an urgent need to find a cure.”
Self-citationTreatment of SARS with human interferons
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13973-6 · Cited by 467
Flavonoid Baicalin Inhibits HIV-1 Infection at the Level of Viral Entry
Li, B. Q., Fu, T., Dongyan, Y., Mikovits, J. A., Ruscetti, F. W., & Wang, J. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3485 · Cited by 258
Early diagnosis of SARS Coronavirus infection by real time RT-PCR
Poon, L. L. M., Chan, K. H., Wong, O. K., Yam, W. C., Yuen, K. Y., Guan, Y., Lo, Y. M. D., & Peiris, J. S. M. (2003) · Journal of Clinical Virology · doi:10.1016/j.jcv.2003.08.004 · Cited by 198
Self-citationBaicalin, an inhibitor of HIV-1 production in vitro
Kitamura, K., Honda, M., Yoshizaki, H., Yamamoto, S., Nakane, H., Fukushima, M., Ono, K., & Tokunaga, T. (1998) · Antiviral Research · doi:10.1016/s0166-3542(97)00069-7 · Cited by 168
Douglas, R. M., Moore, B. W., Miles, H. B., Davies, L. M., Graham, N. M. H., Ryan, P., Worswick, D. A., & Albrecht, J. K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198601093140201 · Cited by 167
Cited by
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,187
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Virology, Epidemiology, Pathogenesis, and Control of COVID-19
Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., & Duan, G. (2020) · Viruses · doi:10.3390/v12040372 · Cited by 1,603
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Self-citationPotential interventions for novel coronavirus in China: A systematic review
Zhang, L., & Liu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25707 · Cited by 1,348
The Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Weiss, S. R., & Navas-Martin, S. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.4.635-664.2005 · Cited by 1,256
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection
Cheng, V. C. C., Lau, S. K. P., Woo, P. C. Y., & Yuen, K. Y. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-07 · Cited by 1,192
Self-citationCoronavirus disease 2019 (COVID-19): current status and future perspectives
Li, H., Liu, S.-M., Yu, X.-H., Tang, S.-L., & Tang, C.-K. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105951 · Cited by 1,156
Severe acute respiratory syndrome
Peiris, J. S. M., Guan, Y., & Yuen, K. Y. (2004) · Nature Medicine · doi:10.1038/nm1143 · Cited by 1,139
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Lavergne, V., Baden, L., Cheng, V. C.-C., Edwards, K. M., Gandhi, R., Muller, W. J., O’Horo, J. C., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa478 · Cited by 1,033
Self-citationYang, Y., Islam, M. S., Wang, J., Li, Y., & Chen, X. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.45538 · Cited by 960
Horby, P. W., Mafham, M., Bell, J. L., Linsell, L., Staplin, N., Emberson, J., Palfreeman, A., Raw, J., Elmahi, E., Prudon, B., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32013-4 · Cited by 709
Elens, L., Langman, L. J., Hesselink, D. A., Bergan, S., Moes, D. J. A. R., Molinaro, M., Venkataramanan, R., & Lemaitre, F. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000761 · Cited by 677
Pang, J., Wang, M. X., Ang, I. Y. H., Tan, S. H. X., Lewis, R. F., Chen, J. I.-P., Gutierrez, R. A., Gwee, S. X. W., Chua, P. E. Y., Yang, Q., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030623 · Cited by 553
Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice)
Zhang, Q., & Ye, M. (2009) · Journal of Chromatography A · doi:10.1016/j.chroma.2008.07.072 · Cited by 549
Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
HO, T., WU, S., CHEN, J., LI, C., & HSIANG, C. (2007) · Antiviral Research · doi:10.1016/j.antiviral.2006.04.014 · Cited by 516
Type 1 interferons as a potential treatment against COVID-19
Sallard, E., Lescure, F.-X., Yazdanpanah, Y., Mentre, F., & Peiffer-Smadja, N. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104791 · Cited by 509
Yao, T., Qian, J., Zhu, W., Wang, Y., & Wang, G. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25729 · Cited by 469
Antiviral effects of Glycyrrhiza species
Fiore, C., Eisenhut, M., Krausse, R., Ragazzi, E., Pellati, D., Armanini, D., & Bielenberg, J. (2008) · Phytotherapy Research · doi:10.1002/ptr.2295 · Cited by 458
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
Giudicessi, J. R., Noseworthy, P. A., Friedman, P. A., & Ackerman, M. J. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.03.024 · Cited by 394
Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
Chan, J. F. W., Chan, K.-H., Kao, R. Y. T., To, K. K. W., Zheng, B.-J., Li, C. P. Y., Li, P. T. W., Dai, J., Mok, F. K. Y., Chen, H., et al. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.09.029 · Cited by 385
Self-citationShannon, A., Le, N. T.-T., Selisko, B., Eydoux, C., Alvarez, K., Guillemot, J.-C., Decroly, E., Peersen, O., Ferron, F., & Canard, B. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104793 · Cited by 352
Islam, R., Parves, M. R., Paul, A. S., Uddin, N., Rahman, M. S., Mamun, A. A., Hossain, M. N., Ali, M. A., & Halim, M. A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1761883 · Cited by 338
Roles of flavonoids against coronavirus infection
Russo, M., Moccia, S., Spagnuolo, C., Tedesco, I., & Russo, G. L. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109211 · Cited by 323
Bailly, C., & Vergoten, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107618 · Cited by 301
Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V. J., & Feldmann, H. (2013) · Scientific Reports · doi:10.1038/srep01686 · Cited by 273
Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines
Ang, L., Lee, H. W., Choi, J. Y., Zhang, J., & Lee, M. S. (2020) · Integrative Medicine Research · doi:10.1016/j.imr.2020.100407 · Cited by 258
Structure and Inhibition of the SARS Coronavirus Envelope Protein Ion Channel
Pervushin, K., Tan, E., Parthasarathy, K., Lin, X., Jiang, F. L., Yu, D., Vararattanavech, A., Soong, T. W., Liu, D. X., & Torres, J. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000511 · Cited by 253
Nucleoside analogues for the treatment of coronavirus infections
Pruijssers, A. J., & Denison, M. R. (2019) · Current Opinion in Virology · doi:10.1016/j.coviro.2019.04.002 · Cited by 196
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Fajgenbaum, D. C., Khor, J. S., Gorzewski, A., Tamakloe, M.-A., Powers, V., Kakkis, J. J., Repasky, M., Taylor, A., Beschloss, A., Hernandez-Miyares, L., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00303-8 · Cited by 52
Liu, Y., Wang, H., & Cai, X. (2015) · Journal of Food Science and Technology · doi:10.1007/s13197-014-1275-0 · Cited by 51
Brinza, I., Ayoub, I. M., Eldahshan, O. A., & Hritcu, L. (2021) · Plants · doi:10.3390/plants10061245 · Cited by 29
Metadata
- Authors
- Chen, F., Chan, K. H., Jiang, Y., Kao, R. Y. T., Lu, H. T., Fan, K. W., Cheng, V. C. C., Tsui, W. H. W., Hung, I. F. N., & Lee, T. S. W.
- Venue
- Journal of Clinical Virology
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 31
- Issue
- 1
- Pages
- 69-75
- ISSN
- 1386-6532 (ISSN-L)
- OpenAlex
- W2166189758
- Cited by
- 534
- References
- 17
- FWCI
- 8.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.